A potential role of ruxolitinib in leukemia

摘要: Introduction: An increased understanding of cellular signaling pathways, like the JAK–STAT pathway, and identification JAK2 V617F mutation in classic Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs), has generated great interest development targeted inhibitors. In a recently completed Phase I–II study, ruxolitinib, selective orally available JAK1 inhibitor, shown efficacy patients with advanced myelofibrosis. Constitutive activation pathway also been implicated other hematological malignancies suggesting potential role JAK kinase inhibitors these malignancies. Areas covered: This article reviews chemistry, pharmacodynamics, pharmacokinetics, clinical efficacy, safety tolerability ruxolitinib. The literature for this was retrieved from PubMed database searches using keywords ‘ruxolitinib’, ‘INCB 018424’, ‘JAK2 inhibitors’ ‘leukemia’. Expert opinion: pl...